Kyverna Therapeutics, Inc. (KYTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2026 Annual Meeting of Stockholders held by Kyverna Therapeutics, Inc. on May 27, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "KYTX". As of the record date (March 30, 2026), there were 60,530,293 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results rather than financial performance data.
Material Changes and Voting Results
Approximately 73% of outstanding shares (43,987,007 shares) were represented at the Annual Meeting, constituting a quorum. Stockholders voted on two proposals:
- Proposal 1 (Election of Directors): Stockholders elected Ian Clark and Christi Shaw as Class II directors to serve until the 2029 annual meeting.
- Ian Clark: 31,505,902 votes For; 3,255,231 votes Withheld; 9,225,874 Broker Non-Votes.
- Christi Shaw: 34,528,865 votes For; 232,268 votes Withheld; 9,225,874 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2026.
- Votes For: 43,830,300
- Votes Against: 80,223
- Abstentions: 76,484
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to report the outcomes of the shareholder vote.
Key Facts for Investor Verification
- Confirmation of the new Board composition with Ian Clark and Christi Shaw serving as Class II directors.
- Verification of BDO USA, P.C.'s role as the independent auditor for the fiscal year ending December 31, 2026.
- Review of the definitive proxy statement filed on April 13, 2026, for detailed background on the proposals.
- Assessment of the high level of shareholder participation (73% quorum) relative to the total outstanding shares.